A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV

NCT06905275 · clinicaltrials.gov ↗

PHASE1

Phase

SUSPENDED

Status

25

Enrollment

NIH

Sponsor class

Stopped Temporarily Closed (Paused) to Accrual

Conditions

HIV-1-infection

Interventions

BIOLOGICAL: 3M-052-AF + Alum
BIOLOGICAL: UVAX-1107
BIOLOGICAL: UVAX-1197

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]